English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe University of Texas MD Anderson Cancer Center today announced an agreement to become a Women’s Cancer Partner with the Union for International Cancer Control (UICC), marking a significant collaboration to improve breast and cervical cancer care worldwide.
Tag: Gynecologic Oncology
Society of Gynecologic Oncology to Host 2024 Annual Meeting on Women’s Cancer® March 16-18 in San Diego, California
Since 1970, health care professionals have convened at the Society of Gynecologic Oncology (SGO)’s Annual Meeting on Women’s Cancer® to discuss the latest in gynecologic cancer care and science, receive educational programming, and network. Members of the entire gynecologic cancer care team who provide treatment and care in the areas of chemotherapy, radiation therapy, surgery, and palliative care attend the SGO Annual Meeting.
TRIAL’S LONG-TERM FOLLOW-UP DATA SHOWS NO DIFFERENCE IN OVERALL SURVIVAL AMONG OVARIAN CANCER PATIENTS WHO DID AND DID NOT RECEIVE PARP INHIBITOR MAINTENANCE THERAPY
After resolving missing data burdens, the ENGOT-OV16/NOVA (NCT01847274) study data shows no difference in overall survival for platinum-sensitive recurrent ovarian cancer (PSROC) patients who received PARP inhibitor niraparib maintenance therapy (MT) and those who did not. Results from the trial were presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute.
GYNECOLOGIC CANCER PATIENTS REPORT TIME-RELATED BURDENS AND FINANCIAL TOXICITIES IMPACT QUALITY OF LIFE
Time-related and financial burdens are detrimental to gynecologic cancer patient and survivor quality of life (QOL), according to two research studies presented yesterday and today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
CLINICAL TRIAL PARTICIPATION ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN OVARIAN CANCER PATIENTS
Clinical trial participation was associated with improved overall survival (OS) compared to standard of care therapy among women with platinum-resistant epithelial ovarian cancer (EOC), according to a research study presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
STUDY FINDS INTRIGUING OUTCOMES IN OVARIAN CANCER PATIENTS TREATED WITH PARP INHIBITORS BEFORE SURGICAL INTERVENTION AND SUBSEQUENT CHEMOTHERAPY
Administering PARP inhibitor (PARPi) olaparib prior to surgical intervention and chemotherapy in ovarian cancer patients – a new approach – is feasible and resulted in favorable surgical options, managed adverse events, and positive health outcomes, according to results from the Neoadjuvant Olaparib Window (NOW) Trial presented today by Shannon Westin, MD et al. at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
Society of Gynecologic Oncology to Host 2023 Annual Meeting on Women’s Cancer® March 25-28 in Tampa, Florida
The 2023 SGO Annual Meeting on Women’s Cancer will be held Saturday, March 25 through Tuesday, March 28 at the Tampa Convention Center in Tampa, Florida. Meeting registration, presenters, session titles and details, press details, and more can be found at sgo.org/annual-meeting.
$1.6M gift to Markey Cancer Center will establish endowed chair in gynecologic oncology
The University of Kentucky Markey Cancer Center has received a $1.6 million gift to establish the John R. van Nagell, Jr. Chair in Gynecologic Oncology. Given from the Telford Foundation to UK HealthCare, the donation will create an endowed chair in honor of John R. van Nagell Jr., M.D., medical director of UK Markey Cancer Center’s Ovarian Cancer Screening Program.
Leading Expert in Women’s Cancers Appointed Director of Gynecologic Oncology at Perlmutter Cancer Center
Nationally renowned surgeon and women’s cancers expert Leslie R. Boyd, MD, has been named director of the Division of Gynecologic Oncology
Gynecologic Oncology Leader Named at New Jersey’s Only NCI-designated Comprehensive Cancer Center
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital (RWJUH), a RWJBarnabas Health facility, have named James K. Aikins, Jr., MD, FACOG, FACS chief of gynecologic oncology at Rutgers Cancer Institute and chief of gynecologic oncology services at RWJUH, New Jersey’s largest academic medical center.
Prominent Gynecologic Oncologist to Direct Cedars-Sinai Women’s Cancer Program
Internationally prominent gynecologic oncologist Kenneth H. Kim, MD, recently was selected to direct the Division of Gynecologic Oncology at Cedars-Sinai Cancer. He also serves as chair of the cancer center’s Committee for Oversight of Training and Education.
Protect Your Cervical Health
Expert from the Gynecologic Oncology Program at Rutgers Cancer Institute of New Jersey shares information about cervical health to highlight cervical health awareness month.
Ovarian Cancer Screening Study Focuses on Early Detection in Women at Low Risk
Atlantic Health System is enrolling women in a landmark study that uses a simple blood test for the CA-125 protein to screen women who are at low risk for ovarian cancer. The purpose of the clinical trial is to help determine whether this test can catch ovarian cancer early in women who would not normally be screened for it. Atlantic Health System hospitals are the only centers in the New York metro region to participate in the study, and have the third highest enrollment numbers in the nation.
At-home screening for ovarian, breast cancers is effective
At-home genetic-testing kits for breast and ovarian cancer risk are just as effective, and in some cases even more so, than the typical protocol for genetic testing, which requires repeated office visits and counseling, according to a study led by UW Medicine researchers.
The Truth About the HPV Vaccine: 7 Myths and Facts You Need to Know
A vaccine is available to protect against human papillomavirus (HPV). HPV is the most common sexually transmitted infection and can cause diseases such as genital warts and cancer.
The HPV vaccine now protects against nine strains of HPV. Research shows that the HPV vaccine is safe and effective.
The HPV vaccine is approved for men and women between the ages of 9 to 45. The HPV vaccine can protect adults from HPV-related diseases, however it provides the most protection when it is given in childhood before someone becomes sexually active.
Parents should talk with their child’s pediatrician about the HPV vaccine. Adult men should ask their primary care provider about the HPV vaccine, and adult women should speak with their gynecologist.
Scientists build genomic research platform to help treat cervical cancer
Yale Cancer Center scientists have built a powerful genomic research platform to study cervical cancer, a disease that often is untreatable if it progresses after surgery or primary chemo-radiation treatment.